Skip to content

Study · Observational study · 2026

7 results

Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.

Arora P, Dabbous F, Udayachalerm S, Saiontz-Martinez C, Zhao Z, O Hartaigh B, Fabricatore A, Bassan M, Alvarez S, Fitch A

Expert review of pharmacoeconomics & outcomes research12 Jan 2026

PMID41524543 (opens in a new tab)DOI10.1080/14737167.2025.2610206 (opens in a new tab)PepBankPUB-41524543
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyOther

    In patients with overweight or obesity and multimorbidity, semaglutide users had 27% lower all-cause total medical costs ($891 vs $1,213 per patient per month) than matched non-users.

    In plain wordsIn people with overweight or obesity and several related conditions, semaglutide users had lower total medical costs than matched people not on obesity drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause total medical costs (PPPM)
    Study

    n: not reported in source

    Comparator
    Matched obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    All-cause total medical cost
    891 USD PPPM
    semaglutide
    All-cause total medical cost
    1213 USD PPPM
    controls

    Source sentences

    Summary
    27% lower all-cause total medical costs ($891 vs $1,213 per patient per month [PPPM])
    1 context sentence
    Summary · context
    A retrospective, observational cohort study using the Komodo Health claims database assessed healthcare resource utilization and medical costs in patients with OW/OB and multimorbidity who received semaglutide compared with propensity-score matched obesity medication non-users (controls).
  2. 02HumanObservational studyOther

    In patients with overweight or obesity and multimorbidity, semaglutide users had 59% lower inpatient costs ($115 vs $283) than matched non-users.

    In plain wordsIn people with overweight or obesity and several related conditions, semaglutide users had lower hospital inpatient costs than matched people not on obesity drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause inpatient costs (PPPM)
    Study

    n: not reported in source

    Comparator
    Matched obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    Inpatient cost
    115 USD PPPM
    semaglutide
    Inpatient cost
    283 USD PPPM
    controls

    Source sentences

    Summary
    59% lower inpatient costs ($115 vs $283)
    1 context sentence
    Summary · context
    A retrospective, observational cohort study using the Komodo Health claims database assessed healthcare resource utilization and medical costs in patients with OW/OB and multimorbidity who received semaglutide compared with propensity-score matched obesity medication non-users (controls).
  3. 03HumanObservational studyOther

    In patients with overweight or obesity and multimorbidity, semaglutide users had 18% lower outpatient costs ($746 vs $906) than matched non-users.

    In plain wordsIn people with overweight or obesity and several related conditions, semaglutide users had lower outpatient costs than matched people not on obesity drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause outpatient costs (PPPM)
    Study

    n: not reported in source

    Comparator
    Matched obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    Outpatient cost
    746 USD PPPM
    semaglutide
    Outpatient cost
    906 USD PPPM
    controls

    Source sentences

    Summary
    18% lower outpatient costs ($746 vs $906) vs. controls (all p < 0.0001).
    1 context sentence
    Summary · context
    A retrospective, observational cohort study using the Komodo Health claims database assessed healthcare resource utilization and medical costs in patients with OW/OB and multimorbidity who received semaglutide compared with propensity-score matched obesity medication non-users (controls).
  4. 04HumanObservational studyOther

    In patients with overweight or obesity and multimorbidity, semaglutide users had 36% lower costs related to obesity-related complications ($522 vs. $812 PPPM) than matched non-users.

    In plain wordsIn people with overweight or obesity and several related conditions, semaglutide users had lower costs for obesity-related complications than matched non-users.

    Peptide
    Semaglutide
    Outcome
    DecreaseORC-related total medical costs (PPPM)
    Study

    n: not reported in source

    Comparator
    Matched obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    ORC-related total medical cost
    522 USD PPPM
    semaglutide
    ORC-related total medical cost
    812 USD PPPM
    controls

    Source sentences

    Summary
    ORC-related total medical costs were 36% lower ($522 vs. $812 PPPM)
    1 context sentence
    Summary · context
    A retrospective, observational cohort study using the Komodo Health claims database assessed healthcare resource utilization and medical costs in patients with OW/OB and multimorbidity who received semaglutide compared with propensity-score matched obesity medication non-users (controls).
  5. 05HumanObservational studyOther

    In patients with overweight or obesity and multimorbidity, semaglutide users had 59% lower inpatient costs related to obesity-related complications ($107 vs $259) than matched non-users.

    In plain wordsIn people with overweight or obesity and several related conditions, semaglutide users had lower inpatient costs for obesity-related complications than matched non-users.

    Peptide
    Semaglutide
    Outcome
    DecreaseORC-related inpatient costs (PPPM)
    Study

    n: not reported in source

    Comparator
    Matched obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    ORC-related inpatient cost
    107 USD PPPM
    semaglutide
    ORC-related inpatient cost
    259 USD PPPM
    controls

    Source sentences

    Summary
    inpatient costs were 59% lower ($107 vs $259)
    1 context sentence
    Summary · context
    A retrospective, observational cohort study using the Komodo Health claims database assessed healthcare resource utilization and medical costs in patients with OW/OB and multimorbidity who received semaglutide compared with propensity-score matched obesity medication non-users (controls).
  6. 06HumanObservational studyOther

    In patients with overweight or obesity and multimorbidity, semaglutide users had 26% lower outpatient costs related to obesity-related complications ($399 vs $540) than matched non-users.

    In plain wordsIn people with overweight or obesity and several related conditions, semaglutide users had lower outpatient costs for obesity-related complications than matched non-users.

    Peptide
    Semaglutide
    Outcome
    DecreaseORC-related outpatient costs (PPPM)
    Study

    n: not reported in source

    Comparator
    Matched obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    ORC-related outpatient cost
    399 USD PPPM
    semaglutide
    ORC-related outpatient cost
    540 USD PPPM
    controls

    Source sentences

    Summary
    outpatient costs were 26% lower ($399 vs $540) among patients taking semaglutide than controls (all p < 0.0001).
    1 context sentence
    Summary · context
    A retrospective, observational cohort study using the Komodo Health claims database assessed healthcare resource utilization and medical costs in patients with OW/OB and multimorbidity who received semaglutide compared with propensity-score matched obesity medication non-users (controls).
  7. 07HumanObservational studyEfficacy outcome

    In patients with overweight or obesity and multimorbidity, semaglutide use was associated with significant improvements in almost all cardiometabolic markers from baseline to Weeks 52 and 104.

    In plain wordsIn people with overweight or obesity and several related conditions, semaglutide use was linked to improvement in almost all heart and metabolic markers over time.

    Peptide
    Semaglutide
    Outcome
    MixedCardiometabolic markers at Weeks 52 and 104
    Study

    n: not reported in source

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Use of semaglutide was associated with significant improvements in almost all cardiometabolic markers assessed from baseline to Weeks 52 and 104.
    1 context sentence
    Summary · context
    A retrospective, observational cohort study using the Komodo Health claims database assessed healthcare resource utilization and medical costs in patients with OW/OB and multimorbidity who received semaglutide compared with propensity-score matched obesity medication non-users (controls).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.